TrialAnnals of the rheumatic diseases2014

Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study.

Mark C Genovese et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.